A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Study of the Safety and Efficacy of a Combination of TAK-559 and Glyburide Compared to Placebo and Glyburide in the Treatment of Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 09 Jun 2013
At a glance
- Drugs Glibenclamide; Imiglitazar
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda Global Research and Development Center
- 10 Jun 2017 Biomarkers information updated
- 08 Oct 2008 New trial record.